https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

Hepatitis C Cure Rates Similar Among Specialists, Primary Care Providers, Nurses Img

Hepatitis C Cure Rates Similar Among Specialists, Primary Care Providers, Nurses

Hepatitis C cure rates with ledipasvir/sofosbuvir (Harvoni) proved nearly identical in patients treated by hepatitis specialists, by primary care providers or by nurse practitioners.

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4 Img

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4

Hepatitis C cure rates using elbasvir/grazoprevir (Zepatier) was 93% in individuals with genotypes 1 or 4, in a study of patients in Asia and Russia.

Study author Sofie Hallager presenting the results

Liver Cancer Risk 60% Lower After SVR in Nationwide Danish Study

Cirrhotic hepatitis-C patients in Denmark had a 63% lower risk of liver cancer and a 76% lower risk of decompensated cirrhosis if they achieved a cure with direct-acting antivirals.

Promo Image

Closing the Gap for Tough-to-Treat Hepatitis C Patients

Despite the diversity of new direct-acting antivirals (DAAs), a tiny number of patients are still left behind. Nancy Reau, M.D., presented a summary of soon-to-be-approved drugs that should work for these tough-to-treat patients.

Heart, Kidney, Bone Disease Rates Higher With Than Without HIV Over 2003-2013 Img

Heart, Kidney, Bone Disease Rates Higher With Than Without HIV Over 2003-2013

Prevalence of cardiovascular disease, renal impairment and fractures or osteoporosis was higher with than without HIV every year from 2003 to 2013.

Promo Image

State Medicaid Programs Ease Illegal Restrictions on Hepatitis C Medications, but More Progress Needed

While restrictions for obtaining hepatitis C drugs through Medicaid programs vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to data presented at the Liver Meeting 2016.

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older Img

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.

No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals Img

No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals

Individuals living with hepatitis C and cirrhosis who are treated with direct-acting antivirals do not face a higher risk of developing liver cancer when compared with untreated individuals, according to a study presented at the Liver Meeting 2016....

HIV Treatment Reduces but Does Not Abolish CNS Inflammation in Past Substance Users Img

HIV Treatment Reduces but Does Not Abolish CNS Inflammation in Past Substance Users

Antiretroviral therapy reduced systemic and central nervous system (CNS) inflammation in past substance users compared with nonusers, according to the results of a study presented at IDWeek 2016.

Mark S. Freedman, M.P.H.

Anal Cancer Screening Uncommon Among HIV-Positive MSM in Care

Anal cancer screening was uncommon -- at only 11% -- among a study of HIV-positive men who have sex with men (MSM) receiving HIV care, despite this community being at a significantly higher risk for anal cancer, according to a study presented at IDWe...